

# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



Version 2.14      Revision Date: 2021/04/09      SDS Number: 50195-00017      Date of last issue: 2020/10/01  
Date of first issue: 2015/01/23

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mirtazapine Disintegrating Formulation

#### Manufacturer or supplier's details

Company : Organon & Co.  
Address : JL Raya Pandaan KM. 48  
Pandaan, Jawa Timur - Indonesia  
Telephone : 551-430-6000  
Emergency telephone number : 215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical


---

### 2. HAZARDS IDENTIFICATION

#### GHS Classification

Acute toxicity (Oral) : Category 4  
Reproductive toxicity : Category 2  
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Nervous system)  
Long-term (chronic) aquatic hazard : Category 3

#### GHS label elements

Hazard pictograms : 

Signal word : Warning

Hazard statements : H302 Harmful if swallowed.  
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.  
H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.  
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.

---

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

P260 Do not breathe dust.  
 P264 Wash skin thoroughly after handling.  
 P270 Do not eat, drink or smoke when using this product.  
 P273 Avoid release to the environment.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
 Contact with dust can cause mechanical irritation or drying of the skin.  
 May form explosive dust-air mixture during processing, handling or other means.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

| Chemical name   | CAS-No.    | Concentration (% w/w) |
|---|------------|-----------------------|
| (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine | 85650-52-8 | >= 10 -< 25           |
| Citric acid   | 77-92-9    | < 10                  |
| Cellulose   | 9004-34-6  | < 10                  |
| Magnesium stearate  | 557-04-0   | < 10                  |

**4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

|   |   |   |
|---|---|---|
| If swallowed  | : | Get medical attention if irritation develops and persists.<br>If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.<br>Never give anything by mouth to an unconscious person.   |
| Most important symptoms and effects, both acute and delayed | : | Harmful if swallowed.<br>Suspected of damaging fertility. Suspected of damaging the unborn child.<br>May cause damage to organs through prolonged or repeated exposure if swallowed.<br>Contact with dust can cause mechanical irritation or drying of the skin.<br>Dust contact with the eyes can lead to mechanical irritation. |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).   |
| Notes to physician  | : | Treat symptomatically and supportively.   |

---

**5. FIREFIGHTING MEASURES**

|   |   |   |
|---|---|---|
| Suitable extinguishing media                  | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                | : | None known.   |
| Specific hazards during fire-fighting         | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health.                   |
| Hazardous combustion products                 | : | Carbon oxides<br>Nitrogen oxides (NO <sub>x</sub> )<br>Metal oxides   |
| Specific extinguishing methods                | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for firefighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |

---

**6. ACCIDENTAL RELEASE MEASURES**

|   |   |   |
|---|---|---|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).  |
| Environmental precautions   | : | Avoid release to the environment.<br>Prevent further leakage or spillage if safe to do so.<br>Retain and dispose of contaminated wash water.<br>Local authorities should be advised if significant spillages cannot be contained. |

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

| Components   | CAS-No.    | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis    |
|--|------------|-------------------------------|--|----------|
| (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1- | 85650-52-8 | TWA                           | 25 µg/m <sup>3</sup>                           | Internal |

# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



Version 2.14      Revision Date: 2021/04/09      SDS Number: 50195-00017      Date of last issue: 2020/10/01  
 Date of first issue: 2015/01/23

|                               |   |                                     |                            |          |
|-------------------------------|---|-------------------------------------|----------------------------|----------|
| a]pyrido[2,3-c][2]benzazepine |   |                                     |                            |          |
|                               |   | Wipe limit                          | 250 µg/100 cm <sup>2</sup> | Internal |
| Cellulose                     | 9004-34-6   | NAB                                 | 10 mg/m <sup>3</sup>       | ID OEL   |
|                               |   | TWA                                 | 10 mg/m <sup>3</sup>       | ACGIH    |
| Magnesium stearate            | 557-04-0  | NAB                                 | 10 mg/m <sup>3</sup>       | ID OEL   |
|                               | Further information: Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals |                                     |                            |          |
|                               |   | TWA (Inhalable particulate matter)  | 10 mg/m <sup>3</sup>       | ACGIH    |
|                               |   | TWA (Respirable particulate matter) | 3 mg/m <sup>3</sup>        | ACGIH    |

**Engineering measures** : Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment: Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation

Version 2.14      Revision Date: 2021/04/09      SDS Number: 50195-00017      Date of last issue: 2020/10/01  
Date of first issue: 2015/01/23

---

|  |   |   |
|--|---|---|
| Appearance                                       | : | powder  |
| Colour   | : | No data available   |
| Odour  | : | No data available   |
| Odour Threshold                                  | : | No data available   |
| pH   | : | No data available   |
| Melting point/freezing point                     | : | No data available   |
| Initial boiling point and boiling range          | : | No data available   |
| Flash point                                      | : | No data available   |
| Evaporation rate                                 | : | No data available   |
| Flammability (solid, gas)                        | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : | No data available   |
| Upper explosion limit / Upper flammability limit | : | No data available   |
| Lower explosion limit / Lower flammability limit | : | No data available   |
| Vapour pressure                                  | : | No data available   |
| Relative vapour density                          | : | No data available   |
| Density  | : | No data available   |
| Solubility(ies)<br>Water solubility              | : | No data available   |
| Partition coefficient: n-octanol/water           | : | No data available   |
| Auto-ignition temperature                        | : | No data available   |
| Decomposition temperature                        | : | No data available   |
| Viscosity<br>Viscosity, dynamic                  | : | No data available   |
| Viscosity, kinematic                             | : | No data available   |
| Explosive properties                             | : | Not explosive   |
| Oxidizing properties                             | : | The substance or mixture is not classified as oxidizing.                        |

# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



Version 2.14      Revision Date: 2021/04/09      SDS Number: 50195-00017      Date of last issue: 2020/10/01  
Date of first issue: 2015/01/23

---

Molecular weight                   : No data available  
Particle size                         : No data available

---

### 10. STABILITY AND REACTIVITY

Reactivity                            : Not classified as a reactivity hazard.  
Chemical stability                   : Stable under normal conditions.  
Possibility of hazardous reac-    : May form explosive dust-air mixture during processing, han-  
tions                                    : dling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid                 : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials             : Oxidizing agents  
Hazardous decomposition         : No hazardous decomposition products are known.  
products

---

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of    : Inhalation  
exposure                               : Skin contact  
  : Ingestion  
  : Eye contact

#### **Acute toxicity**

Harmful if swallowed.

#### **Product:**

Acute oral toxicity                 : Acute toxicity estimate: 1,588 mg/kg  
Method: Calculation method

#### **Components:**

#### **(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Acute oral toxicity                 : LD50 (Rat): 320 - 490 mg/kg

#### **Citric acid:**

Acute oral toxicity                 : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity             : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal  
toxicity

#### **Cellulose:**

Acute oral toxicity                 : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity         : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity             : LD50 (Rabbit): > 2,000 mg/kg

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Citric acid:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Citric acid:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days  
Method : OECD Test Guideline 405

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.



## Mirtazapine Disintegrating Formulation

Version 2.14      Revision Date: 2021/04/09      SDS Number: 50195-00017      Date of last issue: 2020/10/01  
Date of first issue: 2015/01/23

---

**Components:****Magnesium stearate:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Test system: mammalian cells  
Result: negative

Test Type: sister chromatid exchange assay  
Test system: mammalian cells  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Rat  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Citric acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Mouse  
Application Route : Oral  
Exposure time : 18 month(s)  
LOAEL : 200 mg/kg body weight  
Result : equivocal  
Target Organs : Liver

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
LOAEL : 20 mg/kg body weight  
Result : equivocal  
Target Organs : Liver, Thyroid

**Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

**Reproductive toxicity**

Suspected of damaging fertility. Suspected of damaging the unborn child.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Oral  
 Fertility: LOAEL: 15 mg/kg body weight  
 Symptoms: Effect on estrous cycle, Increase of early resorptions  
 Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on foetal development : Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 100 mg/kg body weight  
 Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 40 mg/kg body weight  
 Result: No adverse effects, No teratogenic effects

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

**Citric acid:**

Effects on foetal development : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

reproduction/developmental toxicity screening test  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 422  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative  
 Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Exposure routes : Ingestion  
 Target Organs : Nervous system  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Rat  
 LOAEL : 120 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Nervous system

Species : Dog  
 LOAEL : 15 mg/kg  
 Application Route : Oral  
 Exposure time : 52 Weeks  
 Target Organs : Nervous system  
 Symptoms : Tremors

Species : Dog  
 LOAEL : 20 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Nervous system, Testis  
 Symptoms : Tremors

**Citric acid:**

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

|                   |   |             |
|-------------------|---|-------------|
| Species           | : | Rat         |
| NOAEL             | : | 4,000 mg/kg |
| LOAEL             | : | 8,000 mg/kg |
| Application Route | : | Ingestion   |
| Exposure time     | : | 10 Days     |

**Cellulose:**

|                   |   |                |
|-------------------|---|----------------|
| Species           | : | Rat            |
| NOAEL             | : | >= 9,000 mg/kg |
| Application Route | : | Ingestion      |
| Exposure time     | : | 90 Days        |

**Magnesium stearate:**

|                   |   |                                      |
|-------------------|---|--------------------------------------|
| Species           | : | Rat                                  |
| NOAEL             | : | > 100 mg/kg                          |
| Application Route | : | Ingestion                            |
| Exposure time     | : | 90 Days                              |
| Remarks           | : | Based on data from similar materials |

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

|           |   |  |
|-----------|---|--|
| Ingestion | : | Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation |
|-----------|---|--|

---

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

|                  |   |   |
|------------------|---|---|
| Toxicity to fish | : | LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l<br>Exposure time: 96 h<br>Method: FDA 4.11 |
|------------------|---|---|

|   |   |   |
|---|---|---|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 19.5 mg/l<br>Exposure time: 48 h |
|---|---|---|

|                                  |   |  |
|----------------------------------|---|--|
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201 |
|----------------------------------|---|--|

|  |   |  |
|--|---|--|
|  | : | NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201 |
|--|---|--|

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l  
Exposure time: 31 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.32 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Citric acid:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
Exposure time: 24 h

**Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

## Mirtazapine Disintegrating Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (*Pseudomonas putida*): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Citric acid:**

Biodegradability : Result: Readily biodegradable.  
 Biodegradation: 97 %  
 Exposure time: 28 d  
 Method: OECD Test Guideline 301B

**Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
 Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Bioaccumulation : Species: *Oncorhynchus mykiss* (rainbow trout)  
 Bioconcentration factor (BCF): 334  
 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 2.78

**Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1.72

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Distribution among environ- : log Koc: 4.48

# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



Version 2.14      Revision Date: 2021/04/09      SDS Number: 50195-00017      Date of last issue: 2020/10/01  
Date of first issue: 2015/01/23

---

mental compartments

### Other adverse effects

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

---

## 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

**Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.**

### Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

### Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

### Regulation of the Minister of Trade No. 44 of 2009 on Procurement, Distribution and Supervision of Hazardous Materials

Type of Hazardous Materials Restricted to Import, : Not applicable

---



# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

Distribution and Supervision

**The components of this product are reported in the following inventories:**

|       |   |                |
|-------|---|----------------|
| AICS  | : | not determined |
| DSL   | : | not determined |
| IECSC | : | not determined |

### 16. OTHER INFORMATION

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

**Full text of other abbreviations**

|              |   |   |
|--------------|---|---|
| ACGIH        | : | USA. ACGIH Threshold Limit Values (TLV) |
| ID OEL       | : | Indonesia. Occupational Exposure Limits |
| ACGIH / TWA  | : | 8-hour, time-weighted average           |
| ID OEL / NAB | : | Long term exposure limit                |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - Unit-

# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2020/10/01  |
| 2.14    | 2021/04/09     | 50195-00017 | Date of first issue: 2015/01/23 |

---

ed Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN